TABLE 1.
Susceptibilities of the strains studied to β-lactams
| Strain | Description | Carbapenemase | MICa
(μg/ml) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIP | TZP | CRO | CAZ | ETP | MEM | IMP | ATM | CAZ-AVI | |||
| BK13048 | Clinical isolate | bla KPC-14 | 1,024 | 8 | 16 | 256 | ≤0.03 | ≤0.03 | 0.25 | 64 | >16 |
| KPC2-pET28 | blaKPC-2-harboring E. coli DH10B | bla KPC-2 | 128 | 32 | 8 | 4 | 1 | 2 | 2 | 16 | 0.25 |
| KPC3-pET28 | blaKPC-3-harboring E. coli DH10B | bla KPC-3 | 128 | 32 | 8 | 16 | 1 | 1 | 2 | 32 | 0.25 |
| KPC14-pET28 | blaKPC-14-harboring E. coli DH10B | bla KPC-14 | 32 | 4 | 8 | 256 | ≤0.03 | ≤0.03 | 0.25 | 32 | >16 |
| E. coli DH10B | 1 | 1 | 0.25 | ≤0.03 | ≤0.03 | ≤0.03 | ≤0.125 | ≤0.03 | |||
a
PIP, piperacillin; TZP, piperacillin-tazobactam; CRO, ceftriaxone; CAZ, ceftazidime; ETP, ertapenem; MEM, meropenem; IMP, imipenem; ATM, aztreonam; CAZ-AVI, ceftazidime-avibactam.